Paolo Gallipoli
Queen Mary University of London
H-index: 23
Europe-United Kingdom
Top articles of Paolo Gallipoli
Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts
HemaSphere
2024/1
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
Nature Cancer
2024/4/18
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Blood
2024/1/25
Paolo Gallipoli
H-Index: 17
John Laurie
H-Index: 2
Rob Sellar
H-Index: 12
Rui Zhao
H-Index: 3
Richard Dillon
H-Index: 10
Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the …
Blood
2023/11/28
SCD inhibition preferentially eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy
bioRxiv
2023/8/5
S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
HemaSphere
2023/8/1
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Cancer Discovery
2023/7/7
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia
Bone Marrow Transplantation
2023/7
O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS
Leukemia Research
2023/5/1
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
Nature Communications
2023/4/14
Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia
Science translational medicine
2023/3/1
A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies
Clinical Cancer Research
2023/2/16
Aristeidis Chaidos
H-Index: 20
Manali Kamdar
H-Index: 16
Paolo Gallipoli
H-Index: 17
Michael Dickinson
H-Index: 1
P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
HemaSphere
2022/6/1
The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)
British journal of haematology
2022/3/3
Paolo Gallipoli
H-Index: 17
Jenny Byrne
H-Index: 18
Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML
Blood
2022/11/15
Molecular MRD assessment is strongly prognostic in patients with NPM1 mutated AML receiving venetoclax based non-intensive therapy
Blood
2022/11/15
Real-World Experience of Asciminib: Factors Associated with Response
Blood
2022/11/15
Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia
Blood
2022/11/15
AML gets upSET when its needs are unMet comment
2022/11/10
Paolo Gallipoli
H-Index: 17
AML gets upSET when its dietary needs are unMet
Blood, The Journal of the American Society of Hematology
2022/11/10
Paolo Gallipoli
H-Index: 17
